| 1. | Pharmacological properties of nebivolol
Ipek Komşuoğlu Çelikyurt
doi: 10.5543/ucard.2019.21931 2019; 2 - 1 | Pages 7 - 14
|
|
| REVIEW |
| 2. | 2017 ESC/EACTS Guidelines for the management of valvular heart disease
Helmut Baumgartner, Volkmar Falk, Jeroen J. Bax, Michele De Bonis, Christian Hamm, Per Johan Holm, Bernard Iung, Patrizio Lancellotti, Emmanuel Lansac, Daniel Rodriguez Munoz, Raphael Rosenhek, Johan Sjögren, Pilar Tornos Mas, Alec Vahanian, Thomas Walther, Olaf Wendler, Stephan Windecker, Jose Luis Zamorano
doi: 10.1093/eurheartj/ehx391 2018; 1 - 2 | Pages 1 - 53
|
|
| INVITED REVIEW |
| 3. | Beta-blockers in cardiovascular prevention
Barış Ilerigelen
doi: 10.5543/ucard.2019.00719 2019; 2 - 1 | Pages 1 - 6
|
|
| 4. | Nebivolol in the treatment of systemic hypertension
Fatih Sinan Ertaş
doi: 10.5543/ucard.2019.76486 2019; 2 - 1 | Pages 15 - 19
|
|
| 5. | Approach to secondary prevention patient in the 2019 European Society of Cardiology Dyslipidemia Guide
Meral Kayıkçıoğlu
doi: 10.5543/ucard.2019.98608 2020; 3 - 1 | Pages 7 - 9
|
|
| REVIEW |
| 6. | Sakubitril/valsartan’ın kalp yetersizliğinde yarar sağlayan etki mekanizmaları nelerdir?
Lütfü Bekar
doi: 10.5543/ucard.2020.92485 2020; 3 - 2 | Pages 1 - 3
|
|
| 7. | Guide on advanced heart failure
Sanem Nalbantgil, Yüksel Çavuşoğlu, Bahri Akdeniz, Hakan Altay, Ahmet Çelik, Çağatay Engin, Tolga Sinan Güvenç, Bülent Mutlu, Gökçen Orhan, Bülent Özin, Ahmet Temizhan, Dilek Ural, Nesligül Yıldırım, Mehmet Birhan Yılmaz
doi: 10.5543/ucard.2018.43153 2018; 1 - 1 | Pages 1 - 79
|
|
| 8. | Böbrek fonksiyonlarına göre sakubitril/valsartan yönetimi nasıl yapılmalıdır?
Ahmet Temizhan, Mustafa Arıcı
doi: 10.5543/ucard.2020.77486 2020; 3 - 2 | Pages 72 - 77
|
|
| 9. | Statin intolerance
Özcan Başaran
doi: 10.5543/ucard.2019.09719 2020; 3 - 1 | Pages 20 - 24
|
|
| 10. | Risk scoring and primary prevention
Öner Özdoğan
doi: 10.5543/ucard.2019.69188 2020; 3 - 1 | Pages 3 - 6
|
|
| 11. | Diet and lifestyle modifications
Ümit Yaşar Sinan
doi: 10.5543/ucard.2019.02996 2020; 3 - 1 | Pages 25 - 29
|
|
| 12. | Introduction to 2019 ESC/EAS Guidelines for the Management of Dyslipidema
Lale Tokgözoğlu
doi: 10.5543/ucard.2019.25744 2020; 3 - 1 | Pages 1 - 2
|
|
| 13. | What is the NTproBNP response to sacubitril / Valsartan treatment and how does the NTproBNP response correlate with clinical benefit?
Ilke Sipahi
doi: 10.5543/ucard.2020.83997 2020; 3 - 2 | Pages 86 - 87
|
|
| INVITED REVIEW |
| 14. | Clinical trials with nebivolol in Turkey
Mustafa Kılıçkap
doi: 10.5543/ucard.2019.66375 2019; 2 - 1 | Pages 25 - 30
|
|
| REVIEW |
| 15. | Türkiye’de ki sakubitril/valsartan deneyimi (ARNi-TR) klinik çalışmalardaki verilerle ne kadar örtüşüyor?
Berkay Ekici, Mehdi Zoghi
doi: 10.5543/ucard.2020.02486 2020; 3 - 2 | Pages 123 - 125
|
|
| INVITED REVIEW |
| 16. | Nebivolol in heart failure teatment
Ahmet Temizhan
doi: 10.5543/ucard.2019.33042 2019; 2 - 1 | Pages 20 - 24
|
|
| 17. | Lipid therapy in young and elderly
Ceyhun Ceyhan, Fatih Sivri
doi: 10.5543/ucard.2019.65375 2020; 3 - 1 | Pages 16 - 19
|
|
| REVIEW |
| 18. | Sakubitril/valsartan’ın doz titrasyonu hangi hastada nasıl yapılmalı?
Zeki Öngen, Eser Durmaz
doi: 10.5543/ucard.2020.58077 2020; 3 - 2 | Pages 53 - 55
|
|
| 19. | Lipid lowering therapy in particular patient populations
Barış Güngör
doi: 10.5543/ucard.2019.09797 2020; 3 - 1 | Pages 10 - 15
|
|
| 20. | Sakubitril/valsartan tedavisi sırasında diüretik tedavi yönetimi nasıl olmalı?
Zerrin Yigit
doi: 10.5543/ucard.2020.07279 2020; 3 - 2 | Pages 67 - 69
|
|
